UPDATE 1-Omeros to terminate kidney disease trial as therapy fails late-stage study

[admin]

Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study. An interim analysis showed the drug failed to demonstrate a statistically significant improvement in reducing elevated levels of protein in urine compared to placebo. The company was studying narsoplimab for the treatment of immunoglobulin A (IgA) nephropathy, in which germ-fighting protein builds up in the kidneys.